Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Orchestra Biomed Hldgs Inc (OBIO)

Orchestra Biomed Hldgs Inc (OBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,498
  • Shares Outstanding, K 38,313
  • Annual Sales, $ 2,640 K
  • Annual Income, $ -61,020 K
  • EBIT $ -69 M
  • EBITDA $ -68 M
  • 60-Month Beta 0.64
  • Price/Sales 44.88
  • Price/Cash Flow N/A
  • Price/Book 7.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.49
  • Low Estimate -0.53
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.61 +28.98%
on 05/23/25
3.51 -4.14%
on 06/10/25
+0.46 (+15.86%)
since 05/16/25
3-Month
2.37 +41.77%
on 05/07/25
4.78 -29.64%
on 03/20/25
-0.75 (-18.35%)
since 03/17/25
52-Week
2.37 +41.77%
on 05/07/25
8.87 -62.12%
on 07/18/24
-4.68 (-58.21%)
since 06/17/24

Most Recent Stories

More News
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

MDT : 86.17 (-1.99%)
OBIO : 3.36 (-0.59%)
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

OBIO : 3.36 (-0.59%)
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

OBIO : 3.36 (-0.59%)
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

OBIO : 3.36 (-0.59%)
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT : 86.17 (-1.99%)
OBIO : 3.36 (-0.59%)
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

MDT : 86.17 (-1.99%)
OBIO : 3.36 (-0.59%)
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

OBIO : 3.36 (-0.59%)
Orchestra BioMed to Present at Upcoming Investor Conferences

OBIO : 3.36 (-0.59%)
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

OBIO : 3.36 (-0.59%)
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

OBIO : 3.36 (-0.59%)

Business Summary

Orchestra BioMed Inc. is a biomedical company accelerating high-impact technologies to patients. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy(TM)for the treatment of hypertension and Virtue(R) Sirolimus AngioInfusion(TM) Balloon for the treatment of atherosclerotic...

See More

Key Turning Points

3rd Resistance Point 3.84
2nd Resistance Point 3.62
1st Resistance Point 3.50
Last Price 3.36
1st Support Level 3.16
2nd Support Level 2.94
3rd Support Level 2.82

See More

52-Week High 8.87
Fibonacci 61.8% 6.39
Fibonacci 50% 5.62
Fibonacci 38.2% 4.85
Last Price 3.36
52-Week Low 2.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar